ERIS Lifesciences Ltd
ERISERIS Lifesciences Ltd's earnings have outrun its stock. EPS grew +73.1% in a year against a −25.1% price move.
The sharpest disagreement: annual EPS moved +73.1% against a −25.1% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (27 weeks in) while the P/E sits at the 45th percentile of its own 9-year range. Underneath, the last four quarters read improving — profit +14.4% year on year, and 147% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
ERIS Lifesciences Ltd trades at ₹1,355, in a downtrend and 27 weeks into that stage. That is −5.6% against its own 200-day average. It sits at 14% of a 52-week range of ₹1,285 to ₹1,800. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is in a downtrend — week 27 of stage 4, confirmed. At ₹1,355 it trades −5.6% versus its 200-day average and sits at 14% of its 52-week range (₹1,285–₹1,800).
Against the market, two honest reads. Cumulative: over the last 9.1 years the stock moved +125% while the NIFTY 500 moved +178% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-07-17) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
ERIS Lifesciences Ltd trades at 28.6× P/E, mid-range by its own standards (45th percentile). Its long-run median P/E is 29.6×, measured across 9.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 28.6× is mid-range by its own standards (45th percentile), against a long-run median of 29.6× measured over 9.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +73.1% against a −25.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +11.4%/yr price move, ~+11.7%/yr came from earnings growth and ~−0.3 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 11% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
ERIS Lifesciences Ltd reads as improving on its fundamental arc. Improving — EPS growth bottomed 5 quarters ago at −10.2% and has held its recovery at +64.4%, ROCE holding at 14.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.1% | +22.9% | +20.9% | +18.0% |
| Profit | +72.8% | +20.1% | +12.8% | +17.0% |
| EPS | +73.1% | +16.8% | +11.3% | −41.6% |
| Share price | −25.1% | +20.4% | +11.4% | — |
4-Factor Sector Score
51.6/100 — rank 20 of 43 in Pharma - Formulators · 76% evidence confidence
ERIS Lifesciences Ltd scores 51.6 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 20. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 21 + 14.1 + 11.1 + 5.4 = 51.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
ERIS Lifesciences Ltd reported ₹873 Cr of revenue in the Jun 26 quarter, +12.9% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 18.0% a year. The last full year, FY26, came in at ₹3,129 Cr. The last four reported quarters add to ₹3,229 Cr.
FY26 revenue came in at ₹3,129 Cr (+8.1% on the year), capping 10 years at 18.0% compound. The latest quarter (Jun 26) printed ₹873 Cr, +12.9% year on year — the 11th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +9.5% growth against the decade's 18.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +9.6% over the last 4 quarters against +19.5%/yr over the last 8 — rolling over; TTM profit +62.2% vs +30.1%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
ERIS Lifesciences Ltd's operating margin is 34.0% in the Jun 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 19.0% to 38.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 34.0%, −2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 19.0%–38.0%.
🚨 Why the margin moved: operating margin went −1.9 pp year on year while gross margin went −3.5 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
ERIS Lifesciences Ltd earned ₹143 Cr of net profit in the Jun 26 quarter, +14.4% year on year. It is the 6th consecutive quarter of growth. Full-year FY26 profit was ₹648 Cr. The 10-year compound rate is 17.0%. That is 16.4% of the quarter's revenue. The same quarter a year earlier earned ₹125 Cr.
Jun 26 profit was ₹143 Cr, +14.4% year on year — the 6th consecutive quarter of growth. On the full year, FY26 printed ₹648 Cr (+72.8%), and the 10-year compound rate is 17.0%.
Why profit moved: revenue contributed +12.9% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +63.2% vs revenue +9.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 147% of ERIS Lifesciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹538 Cr of operating cash against ₹648 Cr of profit. After ₹266 Cr of capital spending, ₹272 Cr was left as free cash.
FY26: operating cash of ₹538 Cr against reported profit of ₹648 Cr, leaving free cash of ₹272 Cr after ₹266 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 147% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 147%: the cash cycle stretched 99 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 4.6× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
ERIS Lifesciences Ltd's cash conversion cycle runs 129 days in FY26, up from 30 days in FY21. Capital spending ran ₹3,547 Cr over the last 3 years. At FY26 sales of ₹3,129 Cr each day of that cycle holds about ₹8.6 Cr, so roughly ₹1,106 Cr sits inside the business at any moment.
FY26: debtors at 79 days, inventory at 200 days — roughly 6.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 129 days, looser than FY21's 30.
The full loop: cash goes out to suppliers and production on day 0; stock waits 200 days to sell; customers pay about 79 days after that; and suppliers themselves are paid at 151 days — netting out to the 129-day cycle.
In money terms: at FY26 sales of ₹3,129 Cr, each day of the cycle holds about ₹8.6 Cr — so the 129-day loop keeps roughly ₹1,106 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹3,547 Cr over the last 3 fiscal years against ₹778 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹171 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
ERIS Lifesciences Ltd earns a ROCE of 14% in FY26. That is up from a trough of 11% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 20.7% net margin on 0.42× asset turns.
FY26 ROCE is 14%, recovered from a FY24 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 20.7% net margin × 0.42× asset turns × 1.89× balance-sheet leverage ≈ 16.4% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 11% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
ERIS Lifesciences Ltd carries ₹2,359 Cr of borrowings against ₹3,903 Cr of equity in FY26, a debt-to-equity of 0.60. Operating profit covers the interest bill 6×. Over 5 years borrowings went from ₹7.0 Cr to ₹2,359 Cr. Capital spending ran ₹3,547 Cr across the last 3 of those years.
FY26: borrowings of ₹2,359 Cr against equity of ₹3,903 Cr — a debt-to-equity of 0.60. Operating profit covers the interest bill 6×. Over 5 years borrowings went from ₹7.0 Cr to ₹2,359 Cr while capital spending ran ₹3,547 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 11% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 8.8 points of ERIS Lifesciences Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 5.8% of the company. Domestic institutions moved +4.5 points over the same window, to 20.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −8.8 points over 8 quarters to 5.8%; Domestic institutions: +4.5 points over 8 quarters to 20.7%; Promoters: −0.7 points over 8 quarters to 54.1%.
Why the register moved: rotation — foreign institutions −8.8 points against domestic institutions +4.5 points over 8 quarters, with promoters −0.7 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
ERIS Lifesciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Lupin LtdLUPIN | 74.1/100Favorable setup89% evidence | TURNING | 29.7/35 Revenue 23.1% · PAT 62% · OPM change 10 pp 88% evidence | 21.0/25 ROCE 29.9% · OPM 33% 100% evidence | 16.3/20 P/E 19.4× · PEG 0.54 65% evidence | 7.1/20 RS sector -7.4% · RS bench 9% · 1Y 23.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 29.7 + 21 + 16.3 + 7.1 = 74.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Kwality Pharmaceuticals Ltd539997 | 72.8/100Favorable setup78% evidence | LEADER | 29.0/35 Revenue 35.7% · PAT 71.8% · OPM change 3 pp 83% evidence | 17.8/25 ROCE 24.2% · OPM 25% 76% evidence | 6.4/20 P/E 39.4× · PEG — 50% evidence | 19.6/20 RS sector 51.5% · RS bench 73.2% · 1Y 121.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 17.8 + 6.4 + 19.6 = 72.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Caplin Point Laboratories LtdCAPLIPOINT | 68.3/100Favorable setup96% evidence | LEADER | 19.6/35 Revenue 12.9% · PAT 20.1% · OPM change 1 pp 88% evidence | 18.9/25 ROCE 24.6% · OPM 34% 100% evidence | 12.1/20 P/E 29.8× · PEG 0.99 100% evidence | 17.7/20 RS sector 5.7% · RS bench 24.1% · 1Y 23.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 18.9 + 12.1 + 17.7 = 68.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Bliss GVS Pharma LtdBLISSGVS | 66.9/100Favorable setup78% evidence | LEADER | 27.2/35 Revenue 14.3% · PAT 48.4% · OPM change 6 pp 83% evidence | 13.2/25 ROCE 16.9% · OPM 17% 76% evidence | 6.9/20 P/E 37.5× · PEG — 50% evidence | 19.6/20 RS sector 64.6% · RS bench 87.2% · 1Y 203.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 13.2 + 6.9 + 19.6 = 66.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Glenmark Pharmaceuticals LtdGLENMARK | 65.8/100Favorable setup100% evidence | ASLEEP | 30.5/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 17.5/25 ROCE 39.8% · OPM 20% 100% evidence | 12.2/20 P/E 20.2× · PEG 1.43 100% evidence | 5.6/20 RS sector -10.3% · RS bench 5.6% · 1Y 4.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 30.5 + 17.5 + 12.2 + 5.6 = 65.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.3% and the one-year return is 4.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Emcure Pharmaceuticals LtdEMCURE | 65.4/100Favorable setup71% evidence | LEADER | 24.6/35 Revenue 16.6% · PAT 32.9% · OPM change 0 pp 83% evidence | 17.9/25 ROCE 24% · OPM 19% 76% evidence | 9.4/20 P/E 39.3× · PEG — 15% evidence | 13.5/20 RS sector 7.1% · RS bench 25.6% · 1Y 39.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 17.9 + 9.4 + 13.5 = 65.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Corona Remedies LtdCORONA | 64.5/100Mixed-positive evidence73% evidence | BREAKING OUT | 23.7/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 19.4/25 ROCE 33.3% · OPM 22% 100% evidence | 11.4/20 P/E 60.5× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 12 weeks ahead 0% evidence |
| Exact sum: 23.7 + 19.4 + 11.4 + 10 = 64.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Ajanta Pharma LtdAJANTPHARM | 61.4/100Mixed-positive evidence100% evidence | BREAKING OUT | 21.9/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 18.9/25 ROCE 34.5% · OPM 26% 100% evidence | 5.7/20 P/E 38.2× · PEG 2.31 100% evidence | 14.9/20 RS sector 3.1% · RS bench 21% · 1Y 24.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 18.9 + 5.7 + 14.9 = 61.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 9Zydus Lifesciences LtdZYDUSLIFE | 61.2/100Mixed-positive evidence96% evidence | LEADER | 17.1/35 Revenue 16.8% · PAT 9.7% · OPM change 1 pp 88% evidence | 17.8/25 ROCE 21.1% · OPM 34% 100% evidence | 13.9/20 P/E 20.7× · PEG 1.4 100% evidence | 12.4/20 RS sector -3.3% · RS bench 13.8% · 1Y 15.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 17.8 + 13.9 + 12.4 = 61.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Rubicon Research LtdRUBICON | 60.9/100Mixed-positive evidence69% evidence | BREAKING OUT | 23.9/35 Revenue 36.6% · PAT 84.3% · OPM change 3 pp 88% evidence | 21.4/25 ROCE 28.4% · OPM 23% 100% evidence | 5.6/20 P/E 99.9× · PEG 2.65 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 23.9 + 21.4 + 5.6 + 10 = 60.9 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 11Ipca Laboratories LtdIPCALAB | 58.9/100Mixed-positive evidence78% evidence | BREAKING OUT | 22.2/35 Revenue 7.9% · PAT 51% · OPM change 1 pp 83% evidence | 15.3/25 ROCE 17% · OPM 20% 76% evidence | 11.0/20 P/E 37.6× · PEG — 50% evidence | 10.4/20 RS sector -2% · RS bench 15.1% · 1Y 15.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 15.3 + 11 + 10.4 = 58.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Marksans Pharma LtdMARKSANS | 58.3/100Mixed-positive evidence83% evidence | TURNING | 19.9/35 Revenue 12.5% · PAT 9.7% · OPM change 5 pp 88% evidence | 18.1/25 ROCE 18.8% · OPM 23% 100% evidence | 11.5/20 P/E 28× · PEG 1.41 65% evidence | 8.8/20 RS sector -18.1% · RS bench 30.6% · 1Y 13.4%11 of 11 weeks ahead 70% evidence |
| Exact sum: 19.9 + 18.1 + 11.5 + 8.8 = 58.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Wockhardt LtdWOCKPHARMA | 58.1/100Mixed-positive evidence71% evidence | LEADER | 22.6/35 Revenue 12% · PAT 100% · OPM change 14 pp 65% evidence | 9.0/25 ROCE 7.5% · OPM 23% 100% evidence | 8.7/20 P/E 112× · PEG — 15% evidence | 17.8/20 RS sector 10.5% · RS bench 29.2% · 1Y 16.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 9 + 8.7 + 17.8 = 58.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Accent Microcell LtdACCENTMIC | 58.1/100Mixed-positive evidence63% evidence | LEADER | 17.5/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 16.9/25 ROCE 24.9% · OPM 16% 95% evidence | 9.7/20 P/E 27.8× · PEG — 50% evidence | 14.0/20 RS sector 18.5% · RS bench 37.8% · 1Y 85.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 16.9 + 9.7 + 14 = 58.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Amrutanjan Health Care LtdAMRUTANJAN | 55.9/100Mixed-positive evidence77% evidence | ASLEEP | 20.9/35 Revenue 11.3% · PAT 11.8% · OPM change 4 pp 83% evidence | 17.0/25 ROCE 24.8% · OPM 17% 95% evidence | 14.2/20 P/E 23.1× · PEG — 50% evidence | 3.8/20 RS sector -24.6% · RS bench -18.4% · 1Y -24.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.9 + 17 + 14.2 + 3.8 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16RPG Life Sciences LtdRPGLIFE | 54.0/100Mixed-positive evidence93% evidence | LEADER | 11.8/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.3/25 ROCE 25.7% · OPM 22% 100% evidence | 10.2/20 P/E 39.2× · PEG 1.43 65% evidence | 14.7/20 RS sector 2.5% · RS bench 20.8% · 1Y 11.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 17.3 + 10.2 + 14.7 = 54 · Decision use: Price leads the evidence: RS versus the benchmark is 20.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 17Kilitch Drugs (India) LtdKILITCH | 53.7/100Mixed-positive evidence83% evidence | BREAKING OUT | 18.2/35 Revenue 19.8% · PAT 16% · OPM change 1 pp 83% evidence | 10.7/25 ROCE 14.4% · OPM 25% 95% evidence | 14.0/20 P/E 21.6× · PEG — 50% evidence | 10.8/20 RS sector -10.2% · RS bench 6.2% · 1Y -15%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 10.7 + 14 + 10.8 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Alkem Laboratories LtdALKEM | 53.6/100Mixed-positive evidence78% evidence | TURNING | 19.8/35 Revenue 13.5% · PAT 6.1% · OPM change 2 pp 83% evidence | 16.3/25 ROCE 21.2% · OPM 14% 76% evidence | 11.9/20 P/E 28.2× · PEG — 50% evidence | 5.6/20 RS sector -12.9% · RS bench 3% · 1Y 14.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 16.3 + 11.9 + 5.6 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19FDC LtdFDC | 52.2/100Mixed-positive evidence90% evidence | TURNING | 16.7/35 Revenue 3% · PAT 4.9% · OPM change 7 pp 88% evidence | 14.8/25 ROCE 16.7% · OPM 18% 100% evidence | 15.7/20 P/E 22.5× · PEG 0.93 100% evidence | 5.0/20 RS sector -25.2% · RS bench -0.4% · 1Y -16.2%6 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 14.8 + 15.7 + 5 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20ERIS Lifesciences Ltdthis pageERIS | 51.6/100Mixed-positive evidence76% evidence | TURNING | 21.0/35 Revenue 9.6% · PAT 62.2% · OPM change -2 pp 95% evidence | 14.1/25 ROCE 14.1% · OPM 34% 76% evidence | 11.1/20 P/E 28.6× · PEG — 50% evidence | 5.4/20 RS sector -13.9% · RS bench -10.4% · 1Y -24.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 14.1 + 11.1 + 5.4 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Akums Drugs & Pharmaceuticals LtdAKUMS | 51.0/100Mixed-positive evidence71% evidence | LEADER | 13.9/35 Revenue 5.9% · PAT -25.3% · OPM change 4 pp 83% evidence | 10.3/25 ROCE 14.9% · OPM 13% 76% evidence | 9.6/20 P/E 38.6× · PEG — 15% evidence | 17.2/20 RS sector 11.1% · RS bench 29.9% · 1Y 24.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 10.3 + 9.6 + 17.2 = 51 · Decision use: Price leads the evidence: RS versus the benchmark is 29.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 47.1/100Mixed-negative evidence96% evidence | 11.1/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 19.9/25 ROCE 25.4% · OPM 22% 100% evidence | 3.7/20 P/E 53.8× · PEG 2.34 100% evidence | 12.4/20 RS sector 2.9% · RS bench 23.5% · 1Y 41%6 of 10 weeks ahead 100% evidence | |
| Exact sum: 11.1 + 19.9 + 3.7 + 12.4 = 47.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 23Sun Pharmaceutical Industries LtdSUNPHARMA | 46.4/100Mixed-negative evidence100% evidence | BREAKING OUT | 17.8/35 Revenue 11.4% · PAT 16.5% · OPM change -2 pp 100% evidence | 16.3/25 ROCE 20.5% · OPM 29% 100% evidence | 4.0/20 P/E 37.8× · PEG 3.8 100% evidence | 8.3/20 RS sector -4.7% · RS bench 12.3% · 1Y 17.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 16.3 + 4 + 8.3 = 46.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 24Strides Pharma Science LtdSTAR | 46.1/100Mixed-negative evidence80% evidence | FADING | 16.2/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 12.1/25 ROCE 18.3% · OPM 18% 95% evidence | 11.3/20 P/E 16.3× · PEG — 15% evidence | 6.5/20 RS sector -9.2% · RS bench 6.6% · 1Y 12.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 12.1 + 11.3 + 6.5 = 46.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Torrent Pharmaceuticals LtdTORNTPHARM | 45.5/100Mixed-negative evidence100% evidence | BREAKING OUT | 16.7/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 13.2/25 ROCE 15.2% · OPM 34% 100% evidence | 0.9/20 P/E 87.3× · PEG 5.11 100% evidence | 14.7/20 RS sector 5.4% · RS bench 23.6% · 1Y 41.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 13.2 + 0.9 + 14.7 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 23.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 26Biocon LtdBIOCON | 42.5/100Mixed-negative evidence96% evidence | BREAKING OUT | 12.1/35 Revenue 10.9% · PAT -74.2% · OPM change -1 pp 88% evidence | 10.8/25 ROCE 3.6% · OPM 23% 100% evidence | 9.9/20 P/E 178× · PEG 0.82 100% evidence | 9.7/20 RS sector -7.4% · RS bench 9% · 1Y 8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.1 + 10.8 + 9.9 + 9.7 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Mankind Pharma LtdMANKIND | 42.4/100Mixed-negative evidence100% evidence | BREAKING OUT | 17.1/35 Revenue 14.2% · PAT 8% · OPM change 2 pp 100% evidence | 12.6/25 ROCE 13.5% · OPM 26% 100% evidence | 4.9/20 P/E 47.8× · PEG 2.81 100% evidence | 7.8/20 RS sector -11.1% · RS bench 4.9% · 1Y -5.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 12.6 + 4.9 + 7.8 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Gufic BioSciences LtdGUFICBIO | 41.9/100Mixed-negative evidence90% evidence | TURNING | 19.6/35 Revenue 15.1% · PAT -8.6% · OPM change 6 pp 88% evidence | 12.6/25 ROCE 12.3% · OPM 19% 100% evidence | 2.0/20 P/E 60.9× · PEG 4.78 100% evidence | 7.7/20 RS sector -18.5% · RS bench 14.8% · 1Y 0.7%9 of 11 weeks ahead 70% evidence |
| Exact sum: 19.6 + 12.6 + 2 + 7.7 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Aurobindo Pharma LtdAUROPHARMA | 41.1/100Mixed-negative evidence96% evidence | LEADER | 11.5/35 Revenue 6.1% · PAT 0.6% · OPM change -1 pp 88% evidence | 13.3/25 ROCE 12.8% · OPM 20% 100% evidence | 4.1/20 P/E 25.9× · PEG 2.67 100% evidence | 12.2/20 RS sector 4.4% · RS bench 22.3% · 1Y 40.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 13.3 + 4.1 + 12.2 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Natco Pharma LtdNATCOPHARM | 39.8/100Mixed-negative evidence96% evidence | ASLEEP | 5.1/35 Revenue -8% · PAT -24.6% · OPM change -28 pp 88% evidence | 12.9/25 ROCE 17.1% · OPM 17% 100% evidence | 19.1/20 P/E 11.6× · PEG 0.76 100% evidence | 2.7/20 RS sector -17.3% · RS bench -2.6% · 1Y -5.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 5.1 + 12.9 + 19.1 + 2.7 = 39.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 31Lincoln Pharmaceuticals LtdLINCOLN | 39.4/100Mixed-negative evidence83% evidence | ASLEEP | 11.6/35 Revenue 7.5% · PAT 7.2% · OPM change -3 pp 83% evidence | 14.2/25 ROCE 16.3% · OPM 13% 95% evidence | 9.8/20 P/E 13.2× · PEG — 50% evidence | 3.8/20 RS sector -14.7% · RS bench 0.2% · 1Y 6.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 14.2 + 9.8 + 3.8 = 39.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Zim Laboratories LtdZIMLAB | 39.1/100Mixed-negative evidence76% evidence | LEADER | 6.0/35 Revenue -1.2% · PAT -51.9% · OPM change -6.6 pp 83% evidence | 6.1/25 ROCE 4.8% · OPM 6.8% 95% evidence | 8.7/20 P/E 139× · PEG — 15% evidence | 18.3/20 RS sector 16.5% · RS bench 35.4% · 1Y 0%12 of 12 weeks ahead 100% evidence |
| Exact sum: 6 + 6.1 + 8.7 + 18.3 = 39.1 · Decision use: Price leads the evidence: RS versus the benchmark is 35.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 33Suven Life Sciences LtdSUVEN | 38.4/100Thin evidence · provisional58% evidence | TURNING | 18.2/35 Revenue 14.3% · PAT -72% · OPM change -350 pp 65% evidence | 2.1/25 ROCE -76.9% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.1/20 RS sector -30.9% · RS bench 46.4% · 1Y 9.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 18.2 + 2.1 + 10 + 8.1 = 38.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Indoco Remedies LtdINDOCO | 38.2/100Thin evidence · provisional58% evidence | TURNING | 20.4/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.3/25 ROCE 0.9% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -32.2% · RS bench -9.2% · 1Y -30.8%6 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 4.3 + 10 + 3.5 = 38.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Alembic Pharmaceuticals LtdAPLLTD | 38.1/100Mixed-negative evidence90% evidence | TURNING | 14.4/35 Revenue 10.1% · PAT 15.3% · OPM change -3 pp 88% evidence | 6.9/25 ROCE 12.6% · OPM 12% 100% evidence | 12.3/20 P/E 21.4× · PEG 1.74 100% evidence | 4.5/20 RS sector -24.1% · RS bench -4.7% · 1Y -20.1%2 of 11 weeks ahead 70% evidence |
| Exact sum: 14.4 + 6.9 + 12.3 + 4.5 = 38.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Bajaj Healthcare LtdBAJAJHCARE | 36.0/100Mixed-negative evidence87% evidence | FADING | 9.9/35 Revenue 12.3% · PAT -59.1% · OPM change 1 pp 95% evidence | 10.4/25 ROCE 11.5% · OPM 17% 95% evidence | 10.8/20 P/E 20.1× · PEG — 50% evidence | 4.9/20 RS sector -26.4% · RS bench -12.1% · 1Y -34.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 9.9 + 10.4 + 10.8 + 4.9 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Cipla LtdCIPLA | 35.9/100Mixed-negative evidence100% evidence | BREAKING OUT | 4.9/35 Revenue 1.8% · PAT -37.7% · OPM change -9 pp 100% evidence | 11.3/25 ROCE 15.5% · OPM 17% 100% evidence | 12.1/20 P/E 33.2× · PEG 1.25 100% evidence | 7.6/20 RS sector -14.5% · RS bench 1.3% · 1Y -3.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 4.9 + 11.3 + 12.1 + 7.6 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 38Bharat Parenterals Ltd541096 | 34.7/100Thin evidence · provisional55% evidence | TURNING | 13.5/35 Revenue 1.5% · PAT 37.5% · OPM change -2.7 pp 62% evidence | 3.5/25 ROCE -1.8% · OPM -0.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.7/20 RS sector -20.9% · RS bench 17.8% · 1Y -5.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 13.5 + 3.5 + 10 + 7.7 = 34.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 39Dr Reddys Laboratories LtdDRREDDY | 29.9/100Adverse evidence100% evidence | ASLEEP | 4.1/35 Revenue -0.9% · PAT -44.6% · OPM change -14 pp 100% evidence | 10.7/25 ROCE 13% · OPM 11% 100% evidence | 13.5/20 P/E 29.7× · PEG 1.15 100% evidence | 1.6/20 RS sector -24.3% · RS bench -10.6% · 1Y -10.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 4.1 + 10.7 + 13.5 + 1.6 = 29.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 40Influx Healthtech LtdINFLUX | 65.1/100Thin evidence · provisional50% evidence | BREAKING OUT | 19.1/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 20.3/25 ROCE 40% · OPM 19% 95% evidence | 10.0/20 P/E 33.4× · PEG — 15% evidence | 15.7/20 RS sector 12.1% · RS bench 31.1% · 1Y 90.7%9 of 12 weeks ahead 70% evidence |
| Exact sum: 19.1 + 20.3 + 10 + 15.7 = 65.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 41Syncom Healthcare LtdSYNCOM | 50.5/100Thin evidence · provisional31% evidence | 17.2/35 Revenue -69.4% · PAT 63.5% · OPM change — 16% evidence | 6.9/25 ROCE -20.2% · OPM -225.7% 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.4/20 RS sector 29.1% · RS bench 45.7% · 1Y —9 of 12 weeks ahead to 2021-06-30 70% evidence | |
| Exact sum: 17.2 + 6.9 + 10 + 16.4 = 50.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Fredun Pharmaceuticals Ltd539730 | 47.8/100Thin evidence · provisional49% evidence | ASLEEP | 19.1/35 Revenue — · PAT — · OPM change 4 pp 20% evidence | 14.7/25 ROCE 21.3% · OPM 14% 76% evidence | 9.2/20 P/E 50× · PEG — 15% evidence | 4.8/20 RS sector -45.5% · RS bench 59.4% · 1Y 6.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 14.7 + 9.2 + 4.8 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Sai Parenterals LtdSAIPARENT | 39.1/100Thin evidence · provisional33% evidence | TURNING | 15.2/35 Revenue — · PAT — · OPM change — 16% evidence | 5.3/25 ROCE 6% · OPM 13% 95% evidence | 8.6/20 P/E 170× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 15.2 + 5.3 + 8.6 + 10 = 39.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is ERIS Lifesciences Ltd's share price today?
ERIS Lifesciences Ltd trades at ₹1,355, −25.1% over the past year. The company is valued at ₹18,773 Cr. The stock sits at 14% of its 52-week range of ₹1,285–₹1,800, −5.6% versus its 200-day average. On the tape, the price is in a downtrend, 27 weeks in. — as of 31 July 2026.
What were ERIS Lifesciences Ltd's latest quarterly results?
ERIS Lifesciences Ltd reported revenue of ₹873 Cr and net profit of ₹143 Cr for the Jun 26 quarter. Revenue rose 12.9% and profit rose 14.4% year on year. Earnings per share were ₹10.28. The operating margin was 34.0%, 2.0 pp lower than a year earlier. — as of 31 July 2026.
What is ERIS Lifesciences Ltd's revenue?
ERIS Lifesciences Ltd reported revenue of ₹873 Cr in the Jun 26 quarter, +12.9% year on year. For the full FY26 fiscal year, revenue was ₹3,129 Cr (+8.1%). Over the last 10 years revenue compounded at 18.0% a year. — as of 31 July 2026.
What is ERIS Lifesciences Ltd's profit?
ERIS Lifesciences Ltd earned ₹143 Cr of net profit in the Jun 26 quarter, +14.4% year on year — the 6th straight quarter of growth. Full-year FY26 profit was ₹648 Cr. The operating margin ran 34.0% in the latest quarter. — as of 31 July 2026.
What is ERIS Lifesciences Ltd's market cap?
ERIS Lifesciences Ltd's market capitalisation is ₹18,773 Cr at a share price of ₹1,355. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is ERIS Lifesciences Ltd's P/E ratio?
ERIS Lifesciences Ltd trades at a P/E of 28.6×, at the 45th percentile of its own 9-year range, against a long-run median of 29.6×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does ERIS Lifesciences Ltd pay a dividend?
Yes — ERIS Lifesciences Ltd's dividend payout was 16% of profit in FY26, and it recorded a payout in 7 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is ERIS Lifesciences Ltd overvalued?
On its own history, ERIS Lifesciences Ltd looks mid-range against its own history: its P/E of 28.6× sits at the 45th percentile of its 9-year range (long-run median 29.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is ERIS Lifesciences Ltd growing?
Yes — ERIS Lifesciences Ltd is growing: latest-quarter revenue +12.9% year on year, profit +14.4%, and the margin −2.0 pp at 34.0%. The 10-year compound rates are 18.0% (revenue) and 17.0% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is ERIS Lifesciences Ltd performing?
ERIS Lifesciences Ltd is in a downtrend, 27 weeks in. Its latest quarter's revenue rose 12.9% and profit rose 14.4% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is ERIS Lifesciences Ltd in?
Improving — EPS growth bottomed 5 quarters ago at −10.2% and has held its recovery at +64.4%, ROCE holding at 14.0%. The read comes from the last 12 quarters of growth (revenue growth +9.6% latest, profit growth +62.2% latest, eps growth +64.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is ERIS Lifesciences Ltd in an uptrend?
No — the price is in a downtrend (week 27 of stage 4), trading −5.6% versus its 200-day average and at 14% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is ERIS Lifesciences Ltd beating the market?
Not lately — on a trailing-13-week view ERIS Lifesciences Ltd is currently behind the NIFTY 500 (2 weeks and counting; last ahead the week of 2026-07-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 9.1 years the stock moved +125% against the NIFTY 500's +178% — behind the index over the full window. — as of 31 July 2026.
Will ERIS Lifesciences Ltd's share price go up?
This page publishes no price forecast for ERIS Lifesciences Ltd. What it measures instead: the share price is ₹1,355, the price is in a downtrend 27 weeks in. Its P/E of 28.6× sits at the 45th percentile of its own 9-year range. — as of 31 July 2026.
Who owns ERIS Lifesciences Ltd?
Promoters hold 54.1% of ERIS Lifesciences Ltd, foreign institutions 5.8%, domestic institutions 20.7% and the public 19.4% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 8.8 points over 8 quarters. — as of 31 July 2026.
Does ERIS Lifesciences Ltd have too much debt?
It is moderate — ERIS Lifesciences Ltd's debt-to-equity is 0.60, and operating profit covers the interest bill 6×. FY26 borrowings were ₹2,359 Cr against equity of ₹3,903 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is ERIS Lifesciences Ltd's capex?
ERIS Lifesciences Ltd spent ₹3,547 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹266 Cr, with ₹171 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is ERIS Lifesciences Ltd's cash flow?
ERIS Lifesciences Ltd generated ₹538 Cr of operating cash flow in FY26 and ₹272 Cr of free cash flow after ₹266 Cr of capital spending. Reported profit that year was ₹648 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is ERIS Lifesciences Ltd's profit real cash?
Yes — over the last 3 fiscal years, 147% of ERIS Lifesciences Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹538 Cr against reported profit of ₹648 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is ERIS Lifesciences Ltd in its business cycle?
ERIS Lifesciences Ltd's FY26 operating margin was 36.0%, against a 13-year band of 19.0%–38.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 34.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the ERIS Lifesciences Ltd story?
The sharpest disagreement: annual EPS moved +73.1% against a −25.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is ERIS Lifesciences Ltd a stock worth studying right now?
This is not investment advice. The machine read: ERIS Lifesciences Ltd's earnings have outrun its stock. EPS grew +73.1% in a year against a −25.1% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.